The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

AstraZeneca Provides $44.3 Million in Prescription Savings to Georgia Residents in 2010

Monday, January 31, 2011

AstraZeneca Provides $44.3 Million in Prescription Savings to Georgia Residents in 201011:48 EST Monday, January 31, 2011 WILMINGTON, Del. (Business Wire) -- AstraZeneca (NYSE:AZN) announced today that it provided $44.3 million in savings last year to 30,647 patients in Georgia who participate in its AZ&Me prescription savings programs. Georgia residents filled a total of 227,133 prescriptions under these programs that provide AstraZeneca medicines at no cost to eligible patients. “While the economy appears to be getting stronger, we are still seeing record numbers of patients in our prescription savings programs and they are staying in the programs longer,” said Rich Fante, President AstraZeneca U.S. & Regional VP North America. Nationally, AstraZeneca helped 545,937 patients fill more than 4.1 million prescriptions for $947 million in savings through its AZ&Me prescription savings programs in 2010. AstraZeneca provides free medicines to patients through its AZ&Me prescription savings programs in three ways: Individuals: AstraZeneca provides free medicines to qualifying individuals without prescription drug coverage who make up to $30,000 per year and families of four with $60,000 annual household income. Part D beneficiaries: AstraZeneca provides free medicines for qualifying Medicare Part D patients who make up to $30,000 per year or couples who make up to $40,000 per year. Medicare Part D patients can have their filled prescription mailed to their home or physician's office. Healthcare facilities: AstraZeneca provides free medicines to qualifying non-profit organizations, such as disproportionate share hospitals, community health centers and community free clinics. This program connects patients to the medicines they need at the same time and place they receive their treatment. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business. For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363). AstraZenecaMedia Contact:Katie Lubenow, 302-885-9960